



# 2020 PSOH ANNUAL SCIENTIFIC MEETING

SEPTEMBER 25, 2020 / VIRTUAL

## Attendee Guide

---

**PSOH** | ASCO<sup>®</sup> State/Regional  
Affiliate Program  
Pennsylvania Society of Oncology & Hematology

*This program has been awarded AMA PRA Category 1 Credit <sup>™</sup> by the Pennsylvania Medical Society.*

# IMPORTANT LINKS

**Below are all the links you will need to access any agenda items during the 2020 Virtual Annual Scientific Meeting.**

**Click Here to Access the 2020 Virtual Annual Scientific Meeting & Annual Business Meeting**

**Meeting ID:** 826 0980 1827

**Meeting Passcode:** 494117

**Dial-In Number:** 301-715-8592

**Click Here to Access the 2020 Exhibitor Hub**

Using a Mac? Be sure to set your browser to open on Google Chrome.  
Or, you can copy and paste this URL into any browser: [www.psoh.org/exhibitor-hub](http://www.psoh.org/exhibitor-hub)

**Click Here to Access the e-Posters**

Using a Mac? Be sure to set your browser to open on Google Chrome.  
Or, you can copy and paste this URL into any browser: <http://www.psoh.org/2020-posters>

**Click Here to Access the 11:45 a.m. Lunchtime Non-CME Product Showcase**

DISCUSSION OF BRUKINSA™ FOR ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

*Lori Leslie, MD,  
Director, Indolent Lymphoma and CLL Research Programs  
John Theurer Cancer Center*

**Meeting ID:** 942 5659 6841

**Meeting Passcode:** 690028

**Dial-In Number:** 888-788-0099

# ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Pennsylvania Medical Society and the Pennsylvania Society of Oncology and Hematology. The Pennsylvania Medical Society is accredited by the ACCME to provide continuing medical education for physicians.

The Pennsylvania Medical Society designates this live activity for a maximum of **6.25 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the educational activity.

## Claiming CME Credit:

To obtain a CME certificate, please use the link provided below to view and complete the online post-course survey which is available through our learning management system.

You will need to create a web account for the PAMED website if you don't already have one. Membership in PAMED is not required for a Web account. The information required to create a web account includes first and last names, date of birth, and an email address (cannot be a shared email address – each learner profile must have a distinct email address of record). Entering your license number is optional but is helpful in establishing your learner profile.

Once you have created your account/logged in, you will be redirected to the course and able to view and complete the survey. A CME certificate will be available to download, print, or email after you have completed the survey.

CME Survey Link: <http://learning.pamedsoc.org/sso/enrollwithkey/2020PSOH925>

Please note that you cannot use Internet Explorer to access our learning management system as it is not supported by the platform. You must use Chrome or another browser.

If you have any questions about the process to claim CME, please feel free to contact me at your convenience. If you need assistance creating a website account, please contact our Knowledge Center at 855-PAMED4U (855-726-3348) or [KnowledgeCenter@pamedsoc.org](mailto:KnowledgeCenter@pamedsoc.org).

## Nurse CE:

The Pennsylvania Society of Oncology & Hematology, and the University of Pittsburgh School of Nursing are collaborating to present the 2020 PSOH Annual Scientific Meeting. Professional nurses participating in the activity and completing the evaluation tool may receive a maximum of 6.25 contact hours. The University of Pittsburgh School of Nursing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

# CME DISCLOSURES

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards, the following presenters of this course have indicated that they either do or do not have a relationship which, in the context of their presentation, could be perceived by some as a real or apparent conflict of interest, (e.g., ownership of stock, or honoraria or consulting fees). Those presenters having such relationships do not consider that it will influence their presentation.

Financial relationships reported by members of the Scientific Meeting Planning Committee are provided below. During all phases of planning for the Pennsylvania Society of Oncology and Hematology 2020 Annual Scientific Meeting, areas of conflict were managed through a peer-review process and/or through individual recusal when appropriate.

The Scientific Meeting Planning Committee has reviewed all presenter disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where they exist.

Faculty Name	Company Name	Nature of Relationship
Edward Balaban, DO		Nothing to Disclose
Brian Bourbeau, MBA		Nothing to Disclose
Robert Carlson, MD	National Comprehensive Cancer Network	Employee
Steve Cohen, MD		Nothing to Disclose
Stacie Corcoran, RN, MS		Nothing to Disclose
Crystal Denlinger, MD, FACP	Taiho Oncology Exelixis Bayer	Advisor Advisor Advisor
Jennifer Johnson, MD, PhD, FACP		Nothing to Disclose
Arturo Loaiza-Bonilla, MD, MEd	Massive Bio	Stock
Warren Maley, MD		Nothing to Disclose
Usman Shah, MD		Nothing to Disclose
Colette Shaw, MD		Nothing to Disclose

Planning Committee	Company Name	Nature of Relationship
Moshe Chasky, MD		Nothing to Disclose
Steven Cohen, MD		Nothing to Disclose
John Lister, MD		Nothing to Disclose
Arturo Loaiza-Bonilla, MD, MEd	Massive Bio	Stock
James McCormick, DO	Intuitive Surgical	Proctor and Speaker
Dulabh Monga, MD		Nothing to Disclose
Lauren Klinedinst, CMP		Nothing to Disclose
Marie Queen		Nothing to Disclose
Muhammad Rizvi, MD		Nothing to Disclose
Usman Shah, MD		Nothing to Disclose

Oral Abstract Presenter Name	Company Name	Nature of Relationship
Yazan Samhoury		Nothing to Disclose
Veli Bakalov		Nothing to Disclose

## NOTICE OF DISCLAIMER

The information presented is that of the contributing faculty and does not necessarily represent the views of the Pennsylvania Society of Oncology and Hematology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

The Pennsylvania Society of Oncology and Hematology (PSOH) makes every effort to ensure that speakers are knowledgeable authorities in their fields. Seminar attendees are nevertheless advised that the statements and opinions expressed by seminar speakers are those of the speakers, not PSOH. The speakers' statements and/or opinions should not be construed as PSOH policy or recommendations, and PSOH disclaims any liability or responsibility for the consequences of any actions taken in reliance upon those statements or opinions.

Products/services exhibited by companies or organizations other than the Pennsylvania Society of Oncology and Hematology are not endorsed by PSOH. Further, PSOH disclaims any liability or responsibility for the professional or personal use of such products/services.

# WITH OUR APPRECIATION

---

## **Thank you to our PSOH 2020 Scientific Program Planning Committee**

Moshe Chasky, MD, Program Chair

Steven Cohen, MD

John Lister, MD

Arturo Loaiza-Bonilla, MD, MEd

James McCormick, DO

Dulabh Monga, MD

Muhammad Rizvi, MD

Usman Shah, MD

# AGENDA

Time	Session
<b>7:45 a.m. – 8:00 a.m.</b>	Welcome and Annual Business Meeting
<b>8:00 a.m. – 8:45 a.m.</b>	The MSK Survivorship Program <i>Stacie Corcoran, RN, MS</i>
<b>8:45 a.m. – 9:00 a.m.</b>	Oral Abstract Presentation Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis <i>Yazan Samhouri, MD</i>
<b>9:00 a.m. – 9:45 a.m.</b>	State Legislative Update and Legislator of the Year Award <i>Edward Balaban, DO</i> <i>Arturo Loaiza-Bonilla, MD, MEd</i> <i>Representative Ryan Bizzarro</i>
<b>9:45 a.m. – 10:15 a.m.</b>	Break with Exhibitors <a href="#">Click here to visit the Exhibitor Hub!</a>
<b>10:15 a.m. – 11:00 a.m.</b>	Circulating Tumor DNA in Stage 2 Colon Cancer <i>Arturo Loaiza-Bonilla, MD, MEd</i>
<b>11:00 a.m. – 11:45 a.m.</b>	Updates in Head and Neck Cancer <i>Jennifer Johnson, MD, PhD, FACP</i>
<b>11:45 a.m. – 12:45 p.m.</b>	Non-CME Product Showcase—DISCUSSION OF BRUKINSA™ FOR ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY <a href="#">Click here to join!</a> Passcode: 690028
<b>12:45 a.m. – 1:00 p.m.</b>	Break with Exhibitors <a href="#">Click here to visit the Exhibitor Hub!</a>
<b>1:00 p.m. – 2:00 p.m.</b>	Hepatocellular Carcinoma Panel <i>Steve Cohen, MD</i> <i>Crystal Denlinger, MD, FACP</i> <i>Warren Malley, MD</i> <i>Colette Shaw, MD</i>
<b>2:00 p.m. – 2:15 p.m.</b>	Oral Abstract Presentation Disparities in the Enrollment to Systemic Therapy and Survival for Patients with Multiple Myeloma <i>Veli Bakalov, MD</i>
<b>2:15 p.m. – 2:45 p.m.</b>	Break with Exhibitors <a href="#">Click here to visit the Exhibitor Hub!</a>
<b>2:45 p.m. – 3:30 p.m.</b>	Incorporating Value-Based Care into the NCCN Guidelines <i>Robert Carlson, MD</i>
<b>3:30 p.m. – 3:45 p.m.</b>	Oral Abstract Presentation Outcomes of Treatment for HIV infected Lymphoma Patients: A National Cancer Database (NCDB) Analysis <i>Yazan Samhouri, MD</i>
<b>3:45 p.m. – 4:30 p.m.</b>	Payment Models and Reform on Oncology <i>Brian Bourbeau, MBA</i>
<b>4:30 p.m. – 5:15 p.m.</b>	Review of ASCO's Plenary Session <i>Usman Shah, MD</i>
<b>5:15 p.m. – 5:30 p.m.</b>	Wrap Up <i>Usman Shah, MD</i>

# THANK YOU TO OUR SUPPORTERS

The Pennsylvania Society of Oncology and Hematology gratefully acknowledges the following organizations for supporting our PSOH's 2020 Annual Scientific Meeting:

## 10K Corporate Members

Merck  
Janssen Oncology  
Immunomedics

## 5K Corporate Members

Bristol Myers Squibb  
Sanofi Genzyme  
Pfizer Oncology  
Astellas  
Natera  
Seattle Genetics

## Gold Exhibitors

Deciphera

## Silver Exhibitors

Guardant Health  
Incyte Corporation  
BeiGene  
Tempus  
Pharmacyclics  
Lilly

[Click Here to Visit the Exhibitor Hub](#)

# SCAVENGER HUNT

Complete this form and return to Lauren Klinedinst (lklinedinst@pamedsoc.org) by Monday, September 28 for the chance to win an Apple Watch!



## 10K Corporate Members

### Merck

What year was Merck founded?

---

### Immunomedics

This company has a product symbolic of an icon seen in a Greek War?

---

## 5K Corporate Members

### Bristol Myers Squibb

What drug, in combination with opdivo plus 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations?

---

### Sanofi Genzyme

Category \_\_\_\_\_ recommendation for isatuximab-irfc (Sarclisa)

### Pfizer Oncology

What 3 resources are available if I need assistance obtaining a Pfizer Oncology Product?

---

### Natera

What 3 clinical questions does Signatera answer?

---

### Seattle Genetics

What Year was Seattle Genetics founded?

---



# SCAVENGER HUNT

## Gold Exhibitors

### Deciphera

Qinlock (ripretinib) is a \_\_\_\_\_ kinase inhibitor, indicated for advanced GIST patients treated with \_\_\_\_\_ prior TKIs.

## Silver Exhibitors

### Guardant Health

Is Guardant360CDx FDA Approved and covered by Medicare?

---

### Incyte Corporation

What are the 3 FDA approved INCYTE products?

---

### BeiGene

What is the approved dose of BRUKINSA (zanubrutinib) when treating adult patients with mantle cell lymphoma who have received one prior therapy?

---

### Tempus

How many genes do we sequence in our Solid Tumor xT assay?

---

### Pharmacyclics

What is the only BTK inhibitor with 5+ years of proven long-term efficacy and safety data?

---

### Lilly

What company has a heritage more than 140 years strong: company founded on May 10, 1876?

---

